{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:25:47Z","timestamp":1791390347211,"version":"4.3.3"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jurology.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.juro.2016.12.090","type":"journal-article","created":{"date-parts":[[2016,12,24]],"date-time":"2016-12-24T13:04:39Z","timestamp":1482584679000},"page":"1189-1199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":161,"title":["Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis"],"prefix":"10.1097","volume":"197","author":[{"given":"Roger","family":"Chou","sequence":"first","affiliation":[{"name":"Pacific Northwest Evidence-based Practice Center, Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley","family":"Selph","sequence":"additional","affiliation":[{"name":"Pacific Northwest Evidence-based Practice Center, Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David I.","family":"Buckley","sequence":"additional","affiliation":[{"name":"Pacific Northwest Evidence-based Practice Center, Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongwei","family":"Fu","sequence":"additional","affiliation":[{"name":"Pacific Northwest Evidence-based Practice Center, Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica C.","family":"Griffin","sequence":"additional","affiliation":[{"name":"Pacific Northwest Evidence-based Practice Center, Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Grusing","sequence":"additional","affiliation":[{"name":"Pacific Northwest Evidence-based Practice Center, Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Gore","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Washington, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2016.12.090_bib1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.juro.2016.12.090_bib2","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0140-6736(09)60491-8","article-title":"Bladder cancer","volume":"374","author":"Kaufman","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.juro.2016.12.090_bib3","unstructured":"American Cancer Society: Bladder Cancer; Survival rates for bladder cancer by stage, 2016. Available at http:\/\/www.cancer.org\/cancer\/bladdercancer\/detailedguide\/bladder-cancer-survival-rates."},{"key":"10.1016\/j.juro.2016.12.090_bib4","doi-asserted-by":"crossref","unstructured":"Chang SS, Boorjian SA, Chou R et\u00a0al: Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA\/SUO Guideline, 2016. Available at https:\/\/www.auanet.org\/common\/pdf\/education\/clinical-guidance\/Non-Muscle-Invasive-Bladder-Cancer.pdf.","DOI":"10.1016\/j.juro.2016.06.049"},{"key":"10.1016\/j.juro.2016.12.090_bib5","doi-asserted-by":"crossref","first-page":"446","DOI":"10.6004\/jnccn.2013.0059","article-title":"Bladder cancer","volume":"11","author":"Clark","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.juro.2016.12.090_bib6","doi-asserted-by":"crossref","first-page":"5392","DOI":"10.1002\/cncr.26198","article-title":"Compliance with guidelines for patients with bladder cancer: variation in the delivery of care","volume":"117","author":"Chamie","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.juro.2016.12.090_bib7","series-title":"Emerging Approaches to Diagnosis and Treatment of Non-Muscle-Invasive Bladder Cancer. Comparative Effectiveness Reviews, No. 153. Prepared by the Pacific Northwest Evidence-based Practice Center","author":"Chou","year":"2015"},{"key":"10.1016\/j.juro.2016.12.090_bib8","unstructured":"Agency for Healthcare Research and Quality: Methods Guide for Effectiveness and Comparative Effectiveness Reviews. AHRQ Publication No. 10(14)-EHC063-EF. Rockville, Maryland: Agency for Healthcare Research and Quality 2014."},{"key":"10.1016\/j.juro.2016.12.090_bib9","unstructured":"Chou R, Gore J, Buckley D et\u00a0al: Emerging approaches to diagnosis and treatment of non- muscle-invasive bladder cancer. PROSPERO 2014: CRD42014013284. Available at http:\/\/www.crd.york.ac.uk\/PROSPERO\/display_record.asp?ID=CRD42014013284."},{"key":"10.1016\/j.juro.2016.12.090_bib10","unstructured":"U.S. Preventive Services Task Force: U.S. Preventive Services Task Force Procedure Manual. AHRQ Publication No. 08-05118-EF, 2008."},{"key":"10.1016\/j.juro.2016.12.090_bib11","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.jclinepi.2010.08.010","article-title":"Conducting quantitative synthesis when comparing medical interventions: AHRQ and the Effective Health Care Program","volume":"64","author":"Fu","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.juro.2016.12.090_bib12","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.juro.2016.12.090_bib13","doi-asserted-by":"crossref","first-page":"267","DOI":"10.7326\/M13-2886","article-title":"Random-effects meta-analysis of inconsistent effects: a time for change","volume":"160","author":"Cornell","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.juro.2016.12.090_bib14","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.juro.2016.12.090_bib15","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1200\/JCO.1988.6.9.1450","article-title":"Bacillus Calmette-Gu\u00e9rin therapy alters the progression of superficial bladder cancer","volume":"6","author":"Herr","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2016.12.090_bib16","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S0022-5347(05)64556-9","article-title":"Perioperative single dose instillation of epirubicin or interferon-alpha after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: a prospective randomized multicenter study\u2014FinnBladder III long-term results","volume":"168","author":"Rajala","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2016.12.090_bib17","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0022-5347(01)61609-4","article-title":"Transurethral\u00a0resection with perioperative instilation on interferon-alpha or epirubicin for the prophylaxis of recurrent primary superficial bladder cancer: a prospective randomized multicenter study\u2014Finnbladder III","volume":"161","author":"Rajala","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2016.12.090_bib18","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1046\/j.1464-410X.1998.00890.x","article-title":"Efficacy of escalating doses of intravesical interferon alpha-2b in reducing recurrence rate and progression in superficial transitional cell carcinoma","volume":"82","author":"Giannakopoulos","year":"1998","journal-title":"Br J Urol"},{"key":"10.1016\/j.juro.2016.12.090_bib19","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0090-4295(96)00455-4","article-title":"Results at 43 months\u2019 follow-up of a double-blind, randomized, prospective clinical trial using intravesical interferon alpha-2b in the prophylaxis of stage pT1 transitional cell carcinoma of the bladder","volume":"49","author":"Portillo","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.juro.2016.12.090_bib20","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1080\/003655902320131910","article-title":"Intravesical instillations of interferon gamma in the prophylaxis of high risk superficial bladder cancer\u2013results of a controlled prospective study","volume":"36","author":"Stavropoulos","year":"2002","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.juro.2016.12.090_bib21","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.eururo.2014.05.033","article-title":"The effect of age on the efficacy of maintenance bacillus Calmette-Gu\u00e9rin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911","volume":"66","author":"Oddens","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2016.12.090_bib22","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/cncr.24914","article-title":"Gemcitabine versus bacille Calmette-Gu\u00e9rin after initial bacille Calmette-Gu\u00e9rin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial","volume":"116","author":"Di Lorenzo","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.juro.2016.12.090_bib23","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1200\/JCO.2008.20.8199","article-title":"Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance","volume":"28","author":"Addeo","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2016.12.090_bib24","series-title":"Immunotherapy of Urological Tumors","first-page":"69","article-title":"Low dose BCG therapy in superficial bladder cancer: a clinicopathological perspective study","author":"Pagano","year":"1990"},{"key":"10.1016\/j.juro.2016.12.090_bib25","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000281695","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin prophylactic treatment for superficial bladder tumors: results of a controlled prospective study","volume":"45","author":"Melekos","year":"1990","journal-title":"Urol Int"},{"key":"10.1016\/j.juro.2016.12.090_bib26","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/j.1442-2042.2010.02584.x","article-title":"Maintenance intravesical bacillus Calmette-Gu\u00e9rin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: randomized controlled trial by the BCG Tokyo Strain Study Group","volume":"17","author":"Koga","year":"2010","journal-title":"Int J Urol"},{"key":"10.1016\/j.juro.2016.12.090_bib27","first-page":"47","article-title":"Intravesical administration of bacillus Calmette-Gu\u00e9rin in patients with recurrent superficial carcinoma of the urinary bladder: report of a prospective, randomized trial","volume":"69","author":"Pinsky","year":"1985","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.juro.2016.12.090_bib28","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.eururo.2007.04.062","volume":"52","author":"Ojea","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2016.12.090_bib29","first-page":"10","volume":"14","author":"Witjes","year":"1996","journal-title":"Semin Urol Oncol"},{"key":"10.1016\/j.juro.2016.12.090_bib30","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/01.ju.0000080568.91703.18","article-title":"Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study","volume":"170","author":"Di Stasi","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2016.12.090_bib31","first-page":"167","article-title":"A randomized prospective study of intravesical prophylaxis in non-musle invasive bladder cancer at intermediate risk of recurrence: mitomycin chemotherapy vs BCG immunotherapy","volume":"80","author":"Mangiarotti","year":"2008","journal-title":"Arch Ital Urol Androl"},{"key":"10.1016\/j.juro.2016.12.090_bib32","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0090-4295(92)90530-A","article-title":"Bacillus Calmette-Gu\u00e9rin versus mitomycin intravesical therapy in superficial bladder cancer: results of randomized trial after 21 months of follow-up","volume":"40","author":"DeBruyne","year":"1992","journal-title":"Urology, suppl.,"},{"key":"10.1016\/j.juro.2016.12.090_bib33","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S0022-5347(01)65673-8","article-title":"A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin","volume":"156","author":"Krege","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2016.12.090_bib34","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.eururo.2007.02.063","article-title":"Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Gu\u00e9rin (BCG) in patients with non-muscle-invasive bladder carcinoma","volume":"52","author":"Friedrich","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2016.12.090_bib35","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0022-5347(01)65853-1","article-title":"A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma","volume":"156","author":"Lundholm","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2016.12.090_bib36","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/1078-1439(95)00041-F","article-title":"Randomized intergroup comparison of bacillus Calmette-Guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a Southwest Oncology Group study","volume":"1","author":"Lamm","year":"1995","journal-title":"Urol Oncol"},{"key":"10.1016\/j.juro.2016.12.090_bib37","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2016.12.090_bib38","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1464-410x.2001.02306.x","article-title":"A systematic review of intravesical bacillus Calmette-Gu\u00e9rin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer","volume":"88","author":"Shelley","year":"2001","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2016.12.090_bib39","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.urology.2005.12.014","article-title":"Can intravesical bacillus Calmette-Gu\u00e9rin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials","volume":"67","author":"Han","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.juro.2016.12.090_bib40","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eururo.2015.05.050","volume":"69","author":"Sylvester","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2016.12.090_bib41","doi-asserted-by":"crossref","first-page":"477","DOI":"10.6004\/jnccn.2013.0060","article-title":"Perioperative intravesical chemotherapy in non-muscle-invasive bladder cancer: a systematic review and meta-analysis","volume":"11","author":"Abern","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.juro.2016.12.090_bib42","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.eururo.2013.06.009","article-title":"Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review","volume":"64","author":"Perlis","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2016.12.090_bib43","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Gu\u00e9rin for non-muscle-invasive bladder cancer","volume":"56","author":"Malmstr\u00f6m","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2016.12.090_bib44","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.eururo.2008.01.015","article-title":"The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials","volume":"53","author":"Sylvester","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2016.12.090_bib45","first-page":"1471","article-title":"Continuous saline bladder irrigation after transurethral resection is a prophylactic treatment choice for non-muscle invasive bladder tumor","volume":"31","author":"Onishi","year":"2011","journal-title":"Anticancer Res"},{"key":"10.1016\/j.juro.2016.12.090_bib46","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.eururo.2016.01.006","article-title":"Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus bacillus Calmette-Gu\u00e9rin for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive bladder cancer","volume":"69","author":"Arends","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2016.12.090_bib47","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1442-2042.2010.02486.x","article-title":"Evidence-based clinical practice guidelines for bladder cancer (summary - JUA 2009 Edition)","volume":"17","year":"2010","journal-title":"Int J Urol"},{"key":"10.1016\/j.juro.2016.12.090_bib48","series-title":"Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1 and CIS)","author":"Babjuk","year":"2015"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534716320912?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534716320912?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2016.12.090","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T00:31:57Z","timestamp":1651192317000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.juro.2016.12.090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["10.1016\/j.juro.2016.12.090"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2016.12.090","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"The Journal of Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.juro.2016.12.090","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by AMERICAN UROLOGICAL ASSOCIATION EDUCATION AND RESEARCH, INC.","name":"copyright","label":"Copyright"}]}}